Pityriasis Lichenoides Chronica, Role of Streptococcal Infection and Azithromycin

Cairo University30 enrolled

Overview

Primary outcome: The primary outcome at end of study (EOS) is to compare the therapeutic efficacy of Azithromycin in the treatment of pityriasis lichenoides chronica (PLC) with that of a well-documented line of therapy namely narrow band ultra violet B (nbUVB). Secondary outcomes: 1\. To identify the possibility of streptococcal throat infection as a possible underlying etiology in PLC.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Pityriasis Lichenoides

Interventions

AzithromycinDRUG

Patients will be randomly distributed and start taking azithromycin according to the known dose /kg/day for repeated cycles till improvement or reaching the end of study

nbUVBOTHER

The patients will be randomly distributed to start nbUVB sessions and clinical improvement will be compared to that of Azithromycin

Eligibility

Sex: ALLMin age: 6 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients with classic papular eruption of PLC (scaly erythematous papules with mica-like scales) with diagnosis documented histopathologically with or without associated hypopigmented lesions 2. Age: \> 6 years 3. Both sexes. Exclusion Criteria: 1. Patients presenting with only hypopigmented macules whom their skin biopsy revealed PLC. 2. Patients with hypopigmented lesions that reveal mycosis fungoides pathologically. 3. Patients with PLC associated with classic MF. 4. Patients with known absolute contraindications to NB-UVB. 5. Patients with impaired liver and/or kidney functions. 6. Patients with history of any heart disease. 7. Patients with known hypersensitivity to Azithromycin \-

Locations (1)

Kasr Alainy Faculty of Medicine Cairo University

Cairo, Egypt

Outcomes

Primary Outcomes

Efficacy of Azithromycin in treating pityriasis lichenoides chronica

The clinical improvement of patients with PLC will be evaluated after taking 3 to 6 cycles of azithromycin and will be compared to the clinical outcome of patients that had three sessions of nbUVB for six to eight weeks. Side effects will be documented in each group

Time frame: 12 months

Central Contacts

Amira Elbendary, MBBCh, MSc

CONTACT

+201555668584 aelbendary@kasralainy.edu.eg

Elbendary, MBBCh, MSc

CONTACT

amira.elbendary@yahoo.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.